Imunon (IMNN) Competitors $0.90 -0.02 (-1.82%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.00 (+0.28%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends IMNN vs. PDSB, SPRO, OPTN, DYAI, XLO, TNXP, IVVD, ACHL, ICCC, and ALVRShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include PDS Biotechnology (PDSB), Spero Therapeutics (SPRO), OptiNose (OPTN), Dyadic International (DYAI), Xilio Therapeutics (XLO), Tonix Pharmaceuticals (TNXP), Invivyd (IVVD), Achilles Therapeutics (ACHL), ImmuCell (ICCC), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. Imunon vs. PDS Biotechnology Spero Therapeutics OptiNose Dyadic International Xilio Therapeutics Tonix Pharmaceuticals Invivyd Achilles Therapeutics ImmuCell AlloVir PDS Biotechnology (NASDAQ:PDSB) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings. Do analysts prefer PDSB or IMNN? PDS Biotechnology presently has a consensus target price of $11.67, indicating a potential upside of 683.00%. Imunon has a consensus target price of $20.50, indicating a potential upside of 2,186.67%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than PDS Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Imunon 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has stronger earnings & valuation, PDSB or IMNN? Imunon has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPDS BiotechnologyN/AN/A-$42.94M-$1.16-1.28Imunon$500K26.00-$19.51M-$1.89-0.47 Do institutionals and insiders hold more shares of PDSB or IMNN? 26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 9.5% of PDS Biotechnology shares are owned by insiders. Comparatively, 5.0% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor PDSB or IMNN? In the previous week, PDS Biotechnology had 2 more articles in the media than Imunon. MarketBeat recorded 2 mentions for PDS Biotechnology and 0 mentions for Imunon. PDS Biotechnology's average media sentiment score of 0.63 beat Imunon's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the media. Company Overall Sentiment PDS Biotechnology Positive Imunon Neutral Which has more risk and volatility, PDSB or IMNN? PDS Biotechnology has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Is PDSB or IMNN more profitable? PDS Biotechnology's return on equity of -139.57% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets PDS BiotechnologyN/A -139.57% -67.22% Imunon N/A -230.05%-128.98% Does the MarketBeat Community favor PDSB or IMNN? PDS Biotechnology received 53 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 69.61% of users gave PDS Biotechnology an outperform vote. CompanyUnderperformOutperformPDS BiotechnologyOutperform Votes7169.61% Underperform Votes3130.39% ImunonOutperform Votes18100.00% Underperform VotesNo Votes SummaryPDS Biotechnology beats Imunon on 9 of the 16 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.00M$6.58B$5.40B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.4710.0188.8317.53Price / Sales26.00335.371,284.8780.52Price / CashN/A22.6336.6032.90Price / Book0.635.084.964.69Net Income-$19.51M$154.90M$117.89M$224.57M7 Day Performance0.34%2.59%2.74%3.33%1 Month Performance8.01%1.52%3.63%5.33%1 Year Performance57.28%5.49%27.26%22.97% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.0007 of 5 stars$0.90-1.8%$20.50+2,186.7%+60.2%$13.00M$500,000.00-0.4730Short Interest ↑Positive NewsGap UpPDSBPDS Biotechnology1.6813 of 5 stars$1.42+0.7%$11.67+721.6%-67.8%$53.12MN/A-1.2220News CoverageSPROSpero Therapeutics4.6567 of 5 stars$0.95-3.2%$5.00+426.9%-34.5%$51.74M$89.87M13.56150OPTNOptiNose4.3966 of 5 stars$5.02-5.3%$26.00+417.9%-68.7%$50.50M$75.67M-17.93190DYAIDyadic International3.1846 of 5 stars$1.65flat$6.00+263.6%-3.8%$48.82M$3.36M-7.177Positive NewsGap DownXLOXilio Therapeutics3.2382 of 5 stars$1.10flat$4.00+263.6%+67.9%$48.35M$4.62M-0.6470News CoveragePositive NewsTNXPTonix Pharmaceuticals3.1459 of 5 stars$0.26-8.0%$53.50+20,765.8%-97.4%$47.92M$11.29M0.0050IVVDInvivyd3.0097 of 5 stars$0.40-11.7%$7.89+1,875.8%-91.4%$47.75M$11.56M-0.20100Short Interest ↑Negative NewsACHLAchilles Therapeutics2.711 of 5 stars$1.16-2.1%$4.00+244.8%+38.6%$47.68MN/A-0.70250Positive NewsICCCImmuCell0.1056 of 5 stars$5.33+2.7%N/A+3.7%$47.50M$23.84M-10.6670ALVRAlloVir1.651 of 5 stars$0.41-6.6%N/A-40.7%$47.38MN/A-0.47110Stock SplitGap UpHigh Trading Volume Related Companies and Tools Related Companies PDSB Competitors SPRO Competitors OPTN Competitors DYAI Competitors XLO Competitors TNXP Competitors IVVD Competitors ACHL Competitors ICCC Competitors ALVR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMNN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNN Stock Alerts